Skip to main content
Clinical Trials/NCT06431711
NCT06431711
Recruiting
Not Applicable

Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease

Zhejiang Provincial People's Hospital1 site in 1 country2,400 target enrollmentApril 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cerebral Small Vessel Diseases
Sponsor
Zhejiang Provincial People's Hospital
Enrollment
2400
Locations
1
Primary Endpoint
Diagnostic accuracy of fundus OCTA-derived parameters for CSVD
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Cerebral small-vessel disease (CSVD) is a significant contributor to stroke and dementia, primarily impacting individuals over the age of 60. Its prevalence exceeds 70% in the elderly population, imposing a substantial burden on brain health and the economy. Optical coherence tomography angiography (OCTA) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus retinopathy. Current studies have shown that fundus OCTA-derived parameters may have potential in characterizing imaging changes in CSVD. However, the correlation between retinal/choroidal parameters on OCTA and the CSVD imaging markers remains uncertain. FRESH-CSVD is a prospective, observational study that will use fundus OCTA-derived parameters to screen patients with CSVD, explore the relationship between relevant parameters based on OCTA measurements and CSVD, and evaluate the feasibility and clinical value of identification of CSVD through fundus OCTA.

Registry
clinicaltrials.gov
Start Date
April 1, 2024
End Date
March 31, 2034
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Older than 35 years old;
  • Patients who underwent Multimodal MRI with any CSVD imaging marker;
  • Subjects who have signed informed consent.

Exclusion Criteria

  • Patient who was unable to cooperate with examinations;
  • There are known diseases that may cause or worsen CSVD (brain injury, Down syndrome, Alzheimer's disease, Parkinson's disease, etc.);
  • There are known eye diseases or severe underlying fundus lesions that may impact fundus assessment;
  • Suffering from serious systemic diseases, such as heart, liver, kidney diseases or major mental illnesses;
  • Contraindications for imaging examinations
  • Exit Criteria:
  • Not meet the inclusion criteria.
  • For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator.
  • Any adverse or serious adverse events during the study period judged by investigator

Outcomes

Primary Outcomes

Diagnostic accuracy of fundus OCTA-derived parameters for CSVD

Time Frame: baseline ,6-month, and every 1 year, follow-up time up to 5 years

Investigators intend to use these indicators to assess the diagnostic accuracy of fundus OCTA for CSVD: area under the receiver operating characteristic curve (AUROC)

Secondary Outcomes

  • The development of total CSVD burden in MRI(baseline ,6-month, and every 1 year, follow-up time up to 5 years)
  • Number of Patients with cerebrovascular events, cardiovascular events, dementia or death(baseline ,6-month, and every 1 year, follow-up time up to 5 years)

Study Sites (1)

Loading locations...

Similar Trials